1. Scrip

Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge

 
• By Lisa Takagi

The weak yen helped push up both global revenues and costs for major Japanese firms in the fiscal year ended 31 March, while good mainstay growth benefited Daiichi Sankyo and Astellas. Chugai meanwhile had a challenging start to its calendar financial year due to lower pandemic drug stockpiling.

Daiichi Sankyo and Astellas announced its annual performance from FY2023 while Chugai closed its 1Q.
multiple Japanese majors announce annual results while Chugai reported Q1 figures • Source: Shutterstock

Daiichi Sankyo Co., Ltd. again enjoyed double-digit growth led by global blockbuster Enhertu (trastuzumab deruxtecan) last fiscal year, while Astellas Pharma, Inc. marked steady growth for its mainstays.

But Chugai Pharmaceutical Co., Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia